Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Moderately Severe to Severe NPDR”

8 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 8 of 8 results

Testing effectiveness (Phase 2)Study completedNCT05383209
What this trial is testing

Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR)

Who this might be right for
Nonproliferative Diabetic Retinopathy
EyePoint Pharmaceuticals, Inc. 77
Large-scale testing (Phase 3)Ended earlyNCT05066230
What this trial is testing

Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR)

Who this might be right for
Non-proliferative Diabetic Retinopathy
Kodiak Sciences Inc 253
Testing effectiveness (Phase 2)UnknownNCT03258242
What this trial is testing

Keluo Xin Capsule Compare to Placebo in Terms of Efficacy and Safety in Patients With Diabetic Retinopathy

Who this might be right for
Moderately Severe to Severe NPDR
Chengdu Kanghong Pharmaceutical Co., Ltd. 198
Testing effectiveness (Phase 2)Study completedNCT03197870
What this trial is testing

The TIME-2b Study: A Study of AKB-9778 (Razuprotafib), a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)

Who this might be right for
Nonproliferative Diabetic Retinopathy
EyePoint Pharmaceuticals, Inc. 167
Large-scale testing (Phase 3)Ended earlyNCT00248131
What this trial is testing

Extension Study of Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy

Who this might be right for
Diabetic Retinopathy
Novartis Pharmaceuticals 260
Large-scale testing (Phase 3)Study completedNCT02718326
What this trial is testing

Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR)

Who this might be right for
Nonproliferative Diabetic Retinopathy
Regeneron Pharmaceuticals 402
Large-scale testing (Phase 3)Ended earlyNCT00248157
What this trial is testing

Extension Study of the Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy

Who this might be right for
Diabetic Retinopathy
Novartis Pharmaceuticals 105
Testing effectiveness (Phase 2)Study completedNCT04692688
What this trial is testing

Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy

Who this might be right for
Diabetic RetinopathyDiabetic Macular EdemaNPDR - Non Proliferative Diabetic Retinopathy+1 more
Ocuphire Pharma, Inc. 103